HIVE Digital Technologies (HIVE) Announces $90M At-The-Market Share Program

HIVE Digital Technologies Ltd. (NASDAQ: HIVE) is pleased to announce that it has entered into an amended and restated equity distribution agreement (the "Equity Distribution Agreement") with Canaccord Genuity and Stifel GMP (collectively, the "Agents") to amend the Company's at-the-market program (the "ATM Program"). The Equity Distribution Agreement restates and supersedes the previous equity distribution agreement, dated May 10, 2023, between the Company and the Agents expanding the prior Canadian at-the-market program to the United States.

Under the Equity Distribution Agreement, the Company may sell up to US$90 million of common shares of the Company (the "Common Shares"). The Common Shares will be issued by the Company to the public from time to time, through the Agents, at the Company's discretion. The Common Shares sold under the ATM Program, if any, will be sold at the prevailing market price at the time of sale.

Under the Equity Distribution Agreement, sales of Common Shares will be made by the Agents through "at-the-market distributions" as defined in National Instrument 44-102 - Shelf Distributions on the TSX Venture Exchange and the Nasdaq Stock Market. The Company is not obligated to make any sales of Common Shares under the Equity Distribution Agreement. Unless earlier terminated by the Company or the Agents as permitted therein, the Equity Distribution Agreement will terminate as of the date that the aggregate gross sales proceeds of the Common Shares sold under the ATM Program reaches the aggregate amount of US$90 million.

The Company intends to use the net proceeds of the ATM Program, if any, principally for general corporate and working capital requirements, funding ongoing operations, to repay indebtedness outstanding from time to time, to complete future acquisitions, or for other corporate purposes.

The ATM Program is being made pursuant to an amended and restated prospectus supplement (the "Prospectus Supplement") to the Company's short form base shelf prospectus dated May 1, 2023 (the "Base Shelf Prospectus"), amending and restating the prospectus supplement previously filed on May 10, 2023 and a U.S. registration statement on Form F-10 filed on the date hereof (the "Registration Statement"). The Prospectus Supplement has been filed with the securities regulatory authorities in each of the provinces and territories of Canada and is included in the Registration Statement filed with the United States Securities and Exchange Commission.

Copies of the Prospectus Supplement and the Base Shelf Prospectus are available on SEDAR+ at www.sedarplus.com and copies of the Registration Statement, which includes the Prospectus Supplement, are available on EDGAR at www.sec.gov. Copies of such documents may also be obtained from: Canaccord Genuity , Attention: Syndicate Department, 99 High Street, 12th Floor, Boston MA 02110 or by email at [email protected] and Stifel GMP, Attention: ECM 161 Bay Street, Suite 3800, Toronto, ON M5J 2S1 ∙or by email at [email protected]. Such documents contain important information about the ATM Program. Prospective investors should read the Prospectus Supplement and the Base Shelf Prospectus as well as the Registration Statement before making an investment decision.

This news release does not constitute an offer to sell or the solicitation of an offer to buy the Common Shares, nor shall there be any sale of these Common Shares in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

You May Also Be Interested In

• Sinda Ltd. prices IPO at $12 per share on NYSE
• Faraday Future receives U.S. patent for hybrid transmission system
• Definium Therapeutics raises $805M in upsized public offering